• 1
    Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of the femur. Lancet 1959; 2: 9819.
  • 2
    National Institutes of Health. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 7449.
  • 3
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 381S443S.
  • 4
    Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. A population-based study. Arch Intern Med 2002; 162: 12458.
  • 5
    Goldhaber SZ, Tapson VF, for the DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 25962.
  • 6
    Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 14715.
  • 7
    Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ. The Worcester Venous Thromboembolism Study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 7227.
  • 8
    Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 116273.
  • 9
    Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 91330.
  • 10
    Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 27888.
  • 11
    ShojaniaKG, DuncanBW, McDonaldKM, WachterRM, eds. Making Health Care Safer: a Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco-Stanford Evidence-based Practices Center under Contract No. 290-97-0013), AHRQ Publication No. 01-E058, Rockville, MD: Agency for Healthcare Research and Quality. July 2001. [Accessed 17 April 2009]
  • 12
    Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess 2005; 9: ix, 1-95.
  • 13
    International Multicentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 2: 4551.
  • 14
    Leonardi MJ, McGory ML, Ko CY. The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials. Arch Surg 2006; 141: 7909.
  • 15
    Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90: 5478.
  • 16
    Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008; 18: 1626.
  • 17
    Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC, Guske PJ, Kane JM, Gordon N, Sambol NC. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4: 62531.
  • 18
    Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M, for the Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin. An assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008; 168: 180512.
  • 19
    Mahe I, Aghassarian M, Drouet L, Bal dit-Sollier C, Lacut K, Heilmann J-J, Mottier D, Bergmann J-F. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97: 5816.
  • 20
    Turpie AG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 183340.
  • 21
    Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, on behalf of the PEGASUS Investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 121220.
  • 22
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA, for the ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 3259.
  • 23
    Samama CM, Vray M, Barre J, Fiessinger J-N, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D, for the SACRE Study Investigators. Extended venous thromboembolism prophylaxis after total hip replacement. A comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162: 21916.
  • 24
    Sculco TP, Colwell CW, Pellegrini VD, Westrich GH, Bottner F. Prophylaxis against venous thromboembolic disease in patients having a total hip or knee arthroplasty. J Bone Joint Surg 2002; 84-A: 46677.
  • 25
    Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004; 2: 105870.
  • 26
    Westrich GH, Rana AJ, Terry MA, Taveras NA, Kapoor K, Helfet DL. Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. J Orthop Trauma 2005; 19: 23440.
  • 27
    Gonzalez Della Ville A, Serota A, Go G, Sorriaux G, Sculco TP, Sharrock NE, Salvati EA. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res 2006; 444: 14653.
  • 28
    Kakkos SK, Caprini JA, Nicolaides AN, Reddy D. Combined modalities in the prevention of venous thromboembolism: a review of the literature. Phlebology 2006; 21 (Suppl. 1): 238.
  • 29
    Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. J Bone Joint Surg 2007; 89-B: 88792.
  • 30
    Weitz JI, Hirsh J, Samama MM. New Antithrombotic drugs. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 234S56S.
  • 31
    Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 2008; 65: 15209.
  • 32
    Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008; 68: 1699709.
  • 33
    Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 2009; 101: 24.
  • 34
    White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 152531.
  • 35
    Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR. Postdischarge thromboprophylaxis and mortality risk after hip- or knee-replacement surgery. CMAJ 2008; 178: 154554.
  • 36
    Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 915.
  • 37
    Eriksson BI, Lassen MR, for the PENTasaccharide in Hip-FRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 133742.
  • 38
    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2009; 1: 117.
  • 39
    HirshJ, GuyattG, AlbersGW, HarringtonR, SchunemannHJ, eds. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 67S968S.
  • 40
    Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007; 5: 16106.
  • 41
    Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AGG, Glezer S, Thabane L, Sebalt RJ, for the CURVE Investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119: 14555.
  • 42
    Levine RL, Hergenroeder GW, Miller CC, Davies A. Venous thromboembolism prophylaxis in emergency department admissions. J Hosp Med 2007; 2: 7985.
  • 43
    Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann J-F, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, FitzGerald G, Anderson FA, for the IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132: 93645.
  • 44
    Yu H-T, Dylan ML, Lin J, Dubois RW. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64: 6976.
  • 45
    Amin AN, Stemkowski S, Lin J, Yang G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost 2008; 99: 7967.
  • 46
    Cohen AT, Tapson VF, Bergmann J-F, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, for the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 38794.
  • 47
    Kucher N, Spirk D, Kalka C, Mazzolai L, Nobel D, Banyai M, Frauchiger B, Bounameaux H. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients: SWIss Venous ThromboEmbolism Registry (SWIVTER). J Thromb Haemost 2008; 6: 20827.
  • 48
    Burleigh E, Wang C, Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 2006; 63 (Suppl. 6): S239.
  • 49
    Amin A, Hussein M, Battleman D, Lin J, Stemkowski S, Merli GJ. Appropriate VTE prophylaxis is associated with lower direct medical costs among medical and surgical patients in the United States [abstract]. Blood 2008; 112: 4656.
  • 50
    Amin A, Lin J, Yang G, Stemkowski S. Clinical and economic outcomes following full or partial ACCP recommended prophylaxis in cancer patients at risk of venous thromboembolism [abstract]. Blood 2008; 112: 6970.
  • 51
    Seddighzadeh A, Zurawska U, Shetty R, Goldhaber SZ. Venous thromboembolism in patients undergoing surgery: low rates of prophylaxis and high rates of filter insertion. Thromb Haemost 2007; 98: 12205.
  • 52
    Tooher R, Middleton P, Pham C, Fitridge R, Rowe S, Babidge W, Maddern G. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005; 241: 397415.
  • 53
    Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process. J Gen Intern Med 2007; 22: 176270.
  • 54
    Surgical Care Improvement Project – A National Quality Partnership. MedQIC. [Accessed 17 April 2009]
  • 55
    National Consensus Standards for Prevention and Care of Venous Thromboembolism (VTE). The Joint Commission. [Accessed 17 April 2009]
  • 56
    Kakkar AK, Davidson BL, Haas SK, on behalf of the Investigators Against Thromboembolism (INATE) Core Group. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 2217.
  • 57
    Schunemann HJ, Cook D, Grinshaw J, Liberati A, Heffner J, Tapson V, Guyatt G. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl): 688S96S.
  • 58
    Shojania KG, Grimshaw JM. Evidence-based quality improvement: the state of the science. Health Aff 2005; 24: 13850.
  • 59
    Bullock-Palmer RP, Weiss S, Hyman C. Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital. J Hosp Med 2008; 3: 14855.
  • 60
    Stinnett JM, Pendleton R, Skordos L, Wheeler M, Rodgers GM. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78: 16772.
  • 61
    O’Connor C, Adhikari NK, DeCaire K, Friedrich JO. Medical admission order sets to improve deep vein thrombosis prophylaxis rates and other outcomes. J Hosp Med 2009; 4: 819.
  • 62
    McEleny P, Bowie P, Robins JB, Brown RC. Getting a validated guideline into local practice: implementation and audit of the SIGN guideline on the prevention of deep vein thrombosis in a district general hospital. Scott Med J 1998; 43: 235.
  • 63
    Schumock GT, Blackburn JC, Nutescu EA, Walton SM, Finley JM, Lewis RK. Impact of prescribing guidelines for inpatient anticoagulation. Ann Pharmacother 2004; 38: 15705.
  • 64
    Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 96977.
  • 65
    Lecumberri R, Marques M, Diaz-Navarlaz MT, Panizo E, Toledo J, Garcia-Mouriz A, Paramo JA. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thromb Haemost 2008; 100: 699704.
  • 66
    Baroletti S, Munz K, Sonis J, Fanikos J, Fiumara K, Paterno M, Goldhaber SZ. Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis 2008; 25: 14650.
  • 67
    Cohn SL, Adekile A, Mahabir V. Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention. J Hosp Med 2006; 1: 3316.
  • 68
    McMullin J, Cook D, Griffith L, McDonald E, Clarke F, Guyatt G, Gibson J, Crowther M. Minimizing errors of omission: Behavioural rEinforcement of Heparin to Avert Venous Emboli: the BEHAVE study. Crit Care Med 2006; 34: 6949.
  • 69
    Maynard G, Stein J. Preventing Hospital-acquired Venous Thromboembolism: A Guide for Effective Quality Improvement. Prepared by the Society of Hospital Medicine. AHRQ Publication No. 08-0075. Rockville, MD: Agency for Healthcare Research and Quality, August 2008.
  • 70
    Maynard G, Jenkins I, Stone S, Lee J, Fink E, Morris T, Schoenhaus R, Renvall M. Prevention of hospital-acquired venous thromboembolism: prospective validation of a VTE risk assessment model and protocol [abstract]. J Hosp Med 2008; 3(S1): 29.